
Opinion|Videos|April 3, 2025
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.
Advertisement
Episodes in this series

Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
2
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
3
Advanced Practice Providers Leading Quality Improvement in Oncology Care
4
Allowing Emotions in the Room as an Oncology Nurse
5






































